Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucocorticoid-induced osteoporosis: is the bone density decrease the only explanation?

E Lespessailles1, S Poupon, N Adriambelosoa

  • 1Rheumatology Department, Orléans, Porte Madeleine Regional Hospital Center, France.

Joint Bone Spine
|April 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erosive hand osteoarthritis is associated with increased risk of incident osteoporotic fractures in post-menopausal women (QUALYOR cohort).

Osteoarthritis and cartilage·2026
Same author

Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis.

Allergy·2023
Same author

The disability associated with hand osteoarthritis is substantial in a cohort of post-menopausal women: the QUALYOR study.

Osteoarthritis and cartilage·2022
Same author

The French multicentre elevated bone mass study: prevalence and causes.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Efficacy of teriparatide compared with risedronate on FRAX<sup>®</sup>-defined major osteoporotic fractures: results of the VERO clinical trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020

Glucocorticoid therapy increases fracture risk, with lower bone mineral density being a key factor. Bone density at the femoral neck and lumbar spine is crucial for assessing fracture risk in patients on long-term glucocorticoids.

Area of Science:

  • Endocrinology
  • Rheumatology
  • Osteoporosis Research

Background:

  • Glucocorticoids can cause bone fragility through mechanisms beyond just reducing bone mass.
  • Understanding these mechanisms is crucial for managing patients on long-term glucocorticoid therapy.

Purpose of the Study:

  • To investigate the relationship between osteoporotic fractures and bone mineral density (BMD) in patients receiving long-term glucocorticoid treatment.
  • To identify key determinants of fracture risk in this patient population.

Main Methods:

  • A study involving 121 women on long-term glucocorticoid therapy and 125 controls, measuring BMD at the lumbar spine and femoral neck.
  • Radiographs were used to detect fractures in patients with back pain.
  • Statistical analysis, including logistic regression, was performed to identify risk factors for fractures.

Related Experiment Videos

Main Results:

  • Increased cumulative glucocorticoid dose and longer therapy duration correlated with decreased BMD at the femoral neck.
  • Fractures were observed in 46% of patients, with significantly lower BMD in those with fractures, even after adjusting for confounding factors.
  • Age, absence of calcium/vitamin D supplementation, low femoral neck T-score, and glucocorticoid dose were identified as significant predictors of fractures.

Conclusions:

  • Bone mineral density is a critical determinant of fracture risk in patients with glucocorticoid-induced osteoporosis.
  • These findings highlight the importance of BMD monitoring and supplementation in managing patients on long-term glucocorticoid therapy.